Stress-testing the financing plan against regulatory and cash-out risk

After the regulatory gate comes a second gate that is pure finance: reimbursement. A cleared device with no payer code generates little revenue. In the US that means CPT codes and CMS coverage decisions (Medicare's coverage and payment rules); in Europe it means country-by-country health technology assessment and pricing. Reimbursement can add a year or more after clearance.

So the runway must survive not one gate but a chain: regulatory clearance, then reimbursement, then commercial ramp.

The core model: runway versus the gate calendar

Build one timeline with two overlaid tracks.

Track 1: Cash. Monthly burn, current cash, and the resulting "months of runway."

Track 2: Gates. The regulatory submission date, expected review window (base and downside), reimbursement lag, and the point at which meaningful revenue arrives.

The killer metric is the gap between cash-out date and the next value-inflection gate. If runway ends before the gate clears, the next raise happens from a position of weakness (a down round or worse).

A worked example

Assume a Class IIb device firm in Europe, all figures as illustrative estimates:

• Cash on hand: 18 million euros
• Monthly net burnnet burnBurn rate is the speed at which a company spends its cash reserves, usually measured per month, before reaching profitability or raising more funding.Voir la définition complète →: 1.5 million euros
• Runway = 18 / 1.5 = 12 months
• CE mark base case: submission now, clearance in 9 months
• Reimbursement and first real revenue: 6 months after CE mark

Base case cash-out: month 12. First revenue: month 9 + 6 = month 15.

The gap is 3 months of unfunded time even in the base case. The company is already short before anything goes wrong.

Now apply a downside: notified body requests extra clinical data, adding 6 months to review.

• CE mark now lands at month 15
• Revenue at month 21
• Cash-out still at month 12
• Unfunded gap: 9 months

At 1.5 million euros per month, that is 13.5 million euros the firm must raise, on unfavorable terms, into a milestone slip. This is the number the base-case pitch deck hid.

Turn it into a simple stress table

Model three scenarios and read the cash-out month against the revenue month.

| Scenario | Review time | CE mark | First revenue | Cash-out | Unfunded gap |

|---|---|---|---|---|---|

| Base | 9 mo | Mo 9 | Mo 15 | Mo 12 | 3 mo |

| Delay | 15 mo | Mo 15 | Mo 21 | Mo 12 | 9 mo |

| Severe | 21 mo | Mo 21 | Mo 27 | Mo 12 | 15 mo |

The pattern: each incremental month of regulatory delay is not one month of extra burn. It pushes revenue out too, so the funding hole widens faster than the delay itself.

Building the downside distribution, not a single guess

Do not model one delay number. Model a range, because regulatory timing is a distribution.

A light Monte Carlo (running many random scenarios) is enough to see the shape of the risk.

The output is not the point. The point is that a single "9 months" input hides a fat right tail: the probability that the gap exceeds six months. That probability is what you size a raise or a hedge against.

Financial due-diligence checks that expose the risk

When you assess a device company (as investor, acquirer, or lender), these checks surface the timing trap:

• Runway-to-next-gate ratio. Does cash outlast the next regulatory milestone plus reimbursement lag, with a margin (often investors want 6+ months buffer)? If not, ask how the gap is funded.
• Which pathway, which body. A PMA or an MDR Class III device carries far more timing variance than a 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →). Confirm the actual pathway, not the founder's hoped-for pathway.
• Notified body engagement status. In the EU, has a notified body actually accepted the file? Capacity constraints mean acceptance itself is a milestone.
• Reimbursement plan, not just clearance. Is there a coding and coverage strategy with dates, or does the model assume revenue on the day of clearance? Assume the latter is wrong.
• Burn sensitivity. How much can burn be cut without stopping the clinical or regulatory work that unlocks the gate? Cutting the wrong cost extends the gate and worsens the gap.

🎬 [VIDEO: "Understanding the EU Medical Device Regulation (MDR)" - youtube.com - a plain-language overview of MDR classes, notified bodies, and CE marking that grounds the regulatory timeline used in this model]

Hedging the break points

Once the model shows where runway breaks the gate, you have concrete levers.

1. Raise against the downside, not the base case

Size the round to fund past the P75 or P90 review outcome (the delay you would see in 25% or 10% of scenarios), not the median. In the worked example, raising for month-21 revenue rather than month-15 is the difference between negotiating from strength and a fire sale.

2. Use milestone-linked and tranched capital

Tranched financing releases cash as milestones hit (for example, on notified body file acceptance, then on CE mark). This aligns capital with gates but adds risk: if the milestone slips, the tranche may not release exactly when the gap opens. Model the tranche trigger against the downside calendar, not the base case.

3. Non-dilutive bridges

Venture debt or grants can cover a delay gap without repricing equity. Venture debt typically assumes a clear path to a next equity raise, so it hedges a short delay better than an open-ended one. Size it to the gap, not the whole plan.

4. Sequence markets to pull revenue forward

If EU reimbursement is slow, an earlier 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →) in the US (or the reverse) can bring revenue in ahead of the slower gate, shortening the unfunded window. This is a financial decision driven by which gate clears cash fastest.

5. Build burn optionality in advance

Pre-agree which programs pause under a delay scenario. A firm that can cut burn from 1.5 to 1.0 million euros per month without harming the regulatory file buys itself roughly four extra months on the same 18 million euros of cash. Decide this before the delay, not during the panic.

For a grounding in the regulatory structure behind these gates, the FDA device classification overview is a free, authoritative starting point.

Key Takeaways

• Model two clocks, not one. Runway must be tested against the regulatory gate plus reimbursement lag, because revenue arrives after clearance, not on it.
• Delay widens the hole faster than the delay itself. Each month of review slip pushes revenue out too, so a six-month delay can create a nine-month funding gap.
• Size financing to the downside distribution. Raise past the P75 or P90 review outcome; the base-case raise is the classic device-firm mistake.
• Hedge with structure and sequencing. Tranched capital, venture debt bridges, market sequencing, and pre-planned burn cuts each target a specific break point in the model.
• In diligence, demand the reimbursement dates. A clearance with no coverage plan is not a revenue plan. Treat any single regulatory timeline number as an estimate with a fat right tail.